BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 11498841)

  • 1. [Study on the sensitization of acute myeloid leukemia cell to daunorubicin by recombinant human interleukin-3].
    Wang J; Wang Q; Chen X
    Zhonghua Xue Ye Xue Za Zhi; 1999 Jan; 20(1):30-2. PubMed ID: 11498841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effects of bortezomib combined with daunorubicin on proliferation and apoptosis in primary adult acute leukemia].
    Zhou RQ; Gong YP; Zheng BH; Yang X
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2010 Sep; 41(5):789-92. PubMed ID: 21302442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Exploratory study of novel leukemia bone marrow stromal cell adhesion mediated drug resistance model].
    Chen XH; Gao L; Zhang X; Wang JG; Zhang C; Peng XG; Li ZJ; Zeng DF; Liu Y; Si YJ
    Zhonghua Yi Xue Za Zhi; 2007 May; 87(20):1380-3. PubMed ID: 17785056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arsenic trioxide induces apoptosis equally in T lymphoblastoid leukemia MOLT-4 cells and P-gp-expressing daunorubicin-resistant MOLT-4 cells.
    Hu XM; Hirano T; Oka K
    Cancer Chemother Pharmacol; 2003 Feb; 51(2):119-26. PubMed ID: 12647012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
    Lu C; Hassan HT
    Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of multidrug resistance (MDR) proteins and in vitro drug resistance in acute leukemias.
    Fazlina N; Maha A; Jamal R; Zarina AL; Cheong SK; Hamidah H; Ainoon O; Zulkifli SZ; Hamidah NH
    Hematology; 2007 Feb; 12(1):33-7. PubMed ID: 17364990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered intracellular distribution of daunorubicin in immature acute myeloid leukemia cells.
    Lautier D; Bailly JD; Demur C; Herbert JM; Bousquet C; Laurent G
    Int J Cancer; 1997 Apr; 71(2):292-9. PubMed ID: 9139856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells.
    Berman E; McBride M
    Blood; 1992 Jun; 79(12):3267-73. PubMed ID: 1596567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drastic effect of cell density on the cytotoxicity of daunorubicin and cytosine arabinoside.
    Masquelier M; Vitols S
    Biochem Pharmacol; 2004 May; 67(9):1639-46. PubMed ID: 15081863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arsenic trioxide induces apoptosis in cells of MOLT-4 and its daunorubicin-resistant cell line via depletion of intracellular glutathione, disruption of mitochondrial membrane potential and activation of caspase-3.
    Hu XM; Hirano T; Oka K
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):47-58. PubMed ID: 12750841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement of flow-cytometric detection of multidrug-resistant cells by cell-volume normalization of intracellular daunorubicin content.
    Ross DD; Thompson BW; Ordóñez JV; Joneckis CC
    Cytometry; 1989 Mar; 10(2):185-91. PubMed ID: 2714107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antileukaemia effect of rapamycin alone or in combination with daunorubicin on Ph+ acute lymphoblastic leukaemia cell line.
    Yang X; Lin J; Gong Y; Ma H; Shuai X; Zhou R; Guo Y; Shan Q; He G
    Hematol Oncol; 2012 Sep; 30(3):123-30. PubMed ID: 21898527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Study of thrombopoietin and its receptor C-mpl in acute leukemia].
    Guo Y; Bian S; Luo M
    Zhonghua Xue Ye Xue Za Zhi; 1999 Mar; 20(3):120-3. PubMed ID: 11601235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Experimental study of cord blood plasma enhancing the anti-leukemia effect of Ara-C].
    Zhang X; Chen Y; Wang X
    Zhonghua Xue Ye Xue Za Zhi; 1999 May; 20(5):229-31. PubMed ID: 11601208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclosporine diminishes multidrug resistance in K562/ADM cells and improves complete remission in patients with acute myeloid leukemia.
    Li GY; Liu JZ; Zhang B; Wang LX; Wang CB; Chen SG
    Biomed Pharmacother; 2009 Sep; 63(8):566-70. PubMed ID: 19095404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daunorubicin-induced cell kill with 1-hour versus 24-hour infusions: a randomized comparison in children with newly diagnosed acute lymphoblastic leukemia.
    Escherich G; Göbel U; Jorch N; Spaar HJ; Janka-Schaub GE
    Klin Padiatr; 2007; 219(3):134-8. PubMed ID: 17525906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between daunorubicin concentration and apoptosis induction in leukemic cells.
    Masquelier M; Zhou QF; Gruber A; Vitols S
    Biochem Pharmacol; 2004 Mar; 67(6):1047-56. PubMed ID: 15006541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Influence of patients' sera in acute leukemia on proliferation and differentiation of K-562 and HL-60 cells in liquid culture].
    Kuliczkowski K
    Acta Haematol Pol; 1994; 25(2):171-7. PubMed ID: 8067189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nucleus labeling or membrane labeling for studying the proliferation of drug treated cells?
    Boutonnat J; Barbier M; Ronot X; Seigneurin D
    Morphologie; 2000 Jun; 84(265):11-5. PubMed ID: 11048293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A G-quadruplex-interactive agent, telomestatin (SOT-095), induces telomere shortening with apoptosis and enhances chemosensitivity in acute myeloid leukemia.
    Sumi M; Tauchi T; Sashida G; Nakajima A; Gotoh A; Shin-Ya K; Ohyashiki JH; Ohyashiki K
    Int J Oncol; 2004 Jun; 24(6):1481-7. PubMed ID: 15138591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.